Market Overview

2018 Study: Adoptive Transfer of Autologous Lymphocytes Targeting Somatically Mutated Genes: Success in Common Epithelial Cancers with Low Mutation Rates, Gastrointestinal, Bile Duct and Breast Cancer - ResearchAndMarkets.com

Share:

The "Adoptive
Transfer of Autologous Lymphocytes Targeting Somatically Mutated Genes:
Success In Common Epithelial Cancers with Low Mutation Rates,
Gastrointestinal, Bile Duct and Breast Cancers"
report has been
added to ResearchAndMarkets.com's offering.

The report summarizes the current state of clinical research and trials,
explains the impact of ACTs on the treatment of several metastasized
malignancies, and also raises important concerns about the scalability
and compatibility of TILs.

The report includes:

  • An overview of both the problems and phenomenal opportunities with
    cell therapy and immunotherapy in general. While there are several
    biological and also commercial issues still to more completely
    resolve, perhaps the largest challenges are scalability and
    compatibility. Most developers begin by creating cell therapies for
    smaller groups of individuals, and then when they see real promise,
    the issue of scalability is addressed
  • Detailed description about Adoptive Cell Therapy (ACT), how it targets
    the somatic mutations by infusion of autologous or redirected
    tumor-specific T-cells and its impact on the treatment of several
    metastasized malignancies
  • A brief examination of the patent landscape
  • Insight into the structure and function of T lymphocytes,
    identification of the different types of T lymphocytes as well as
    identifying the T Cell growth factor
  • Coverage of a number of clinical trials being conducted to investigate
    the safety and efficacy of Tumor-Infiltrating Lymphocytes (TILs) and
    investigate their use
  • Evaluation of methods to improve TIL yield and tumor reactivity e.g.
    blockage of programmed cell death 1 (PD-1) and the effect of an
    agonistic 4-1BB antibody on TIL growth

Key Topics Covered

1. Adoptive Transfer of Autologous Lymphocytes Targeting Somatically
Mutated Genes

  • Key Findings
  • Tumor-Infiltrating Lymphocytes (TILs): A New and Exciting Era in
    Cancer Treatments
  • Adoptive Cell Transfer (ACT) and Therapeutic TILs
  • Ground-Breaking Management of Advanced Metastatic Breast Cancer
  • Successful Advances in TILs Therapies for Cholangiocarcinoma
  • Hope for Immunotherapy Treatments of Gastrointestinal Cancers
  • Limitations of ACT and Therapeutic TILs
  • Overcoming the Limitations of ACT and Therapeutic TILs
  • Expanding Clinical Trial Portfolio
  • Complexities of the TILs Patent Landscape
  • What's Next for TILs?
  • Outlook and Implications

2. References

3. A Note from the Editor

4. Analyst Credentials

For more information about this report visit https://www.researchandmarkets.com/research/k7twbl/2018_study?w=4

View Comments and Join the Discussion!